Abstract Library

#4281 Automated (artificial intelligence) vs. manual evaluation of the somatostatin-receptor 2A and proliferation marker Ki-67 in neuroendocrine neoplasms: A pilot study

Introduction: Digital image analysis methods are currently being equipped with artificial intelligence (AI). Various AI applications are already in use to determine Ki-67. To date, there is no specialised AI application available to determine the somatostatin-receptor 2A (SSTR2A).

Conference:

Presenting Author:

Authors: Kaemmerer D, Lupp A, Klöppel G, Ayako I, Kasajima A,

Keywords: artificial intelligence, Ki-67, SSTR2A, usability, neuroendocrine neoplasm,

#3290 Intratumoral serotonin might decrease the efficacy of PRRT in ileal neuroendocrine tumors

Introduction: Partial remission can be achieved by peptide receptor radionuclide therapy (PRRT) in only roughly 20% of patients with midgut neuroendocrine tumor (NET). This low remission rate can be due to the radioprotective role of stored intracytoplasmic serotonin in NET cells. If blocked, e.g. by telotristatethyl, PRRT efficacy might be increased.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Prasad V, Klöppel G, Lupp A, Wirtz R, Kaemmerer D,

Keywords: Ileal NET, serotonin, radioprotector, PRRT, immunohistochemistry, TPH1,

#1723 Evaluation of the Somatostatin and CXCR4 Chemokine Receptor Expression in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of Different Origin

Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, whereas the chemokine receptor CXCR4 is considered to be present mainly in highly proliferative and advanced tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lupp A

Authors: Mai R, Kaemmerer D, Sänger J, Neubauer E, Schulz S,

Keywords: somatostatin receptor, CXCR4,

#1484 Neuroendocrine Tumors of the Appendix Are Probably Harmless Neoplasms

Introduction: Appendiceal neuroendocrine tumors (aNETs) have a 5-year survival rate between 74% and 95% according to recent data from Cancer Registry of Norway and the United States, respectively. However, in the daily clinical practice one almost never encounters patients suffering from aNETs with distant metastasis or dying of the disease.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sipos B

Authors: Weysser A, Nieser M, Kloeppel G, Sipos B,

Keywords: NET,

#1302 Differential Somatostatin and CXCR4 Chemokine Receptor Expression in Primary Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) and Their Metastases

Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, where they serve as molecular targets for different imaging and treatment modalities. The chemokine receptor CXCR4, in contrast, is present mainly in highly proliferative and advanced tumors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Kaemmerer D, Träger T, Sänger J, Schulz S, Lupp A,

Keywords: somatostatin receptor, chemokine receptor, sstr,